The nasal mucosa of children with nocturnal enuresis before and after treatment with 1-deamino 8-D-arginine vasopressin spray.
Intranasal administration of 1-deamino 8-D-arginine vasopressin (DDVAP) used for treatment of nocturnal enuresis (NE), might be expected to have various effects on the nasal mucosa, e.g. altering the clearance by the mucociliary apparatus. We evaluated two samples (brushes) of epithelial surface cells from the nasal mucosa, one from each nostril, of 18 children (ten males and eight females) with a mean age of 7.7 years (range: 5-13 years) who were affected by primary NE. Samples were taken before and 1 and 6 months after administration of DDVAP spray. No qualitative changes in the epithelial surface cells from nasal mucosa were recognized and only non-statistically significant increases in percentages of goblet, ciliated, basal and unciliated cells at 1 and 6 months after therapy were observed. Thus, it appears that DDVAP spray can be used for at least 6 months in children without apparent risk of damage to the epithelial surface cells from the nasal mucosa.
Li Volti
S
S
Department of Pediatrics, Città Universitaria, Via S. Sofia 78, 95123, Catania, Italy. livolti@mbox.unict.it
Allegra
E
E
Iozzo
D
D
Palmeri
S
S
Garozzo
R
R
Garozzo
A
A
D000281:Administration, Intranasal; D000293:Adolescent; D000336:Aerosols; D002648:Child; D002675:Child, Preschool; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage*; D004775:Enuresis / Q000188:drug therapy / Q000473:pathology*; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009297:Nasal Mucosa / Q000187:drug effects* / Q000473:pathology; D012076:Renal Agents / Q000008:administration & dosage*
D000336:Aerosols; D012076:Renal Agents; D003894:Deamino Arginine Vasopressin